Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-00610355 in moderate COPD
NCT00783406Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PF-00610355 in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Pfizer. Primary endpoints: Pharmacokinetics of single inhaled dose and Safety and toleration of single inhaled doses. Started Oct 2008; status: completed.
02
Drugs
PF-00610355
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00783406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00783406.